{"disease":{"id":"maintenance-treatment","name":"maintenance treatment"},"drugs":{"marketed":[{"drug_id":"pemetrexed-dipotassium","indication_name":"Maintenance treatment of non-squamous NSCLC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DIPOTASSIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog Metabolic Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"lamotrigine","indication_name":"Bipolar Disorder - Maintenance Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"aclidinium-bromide","indication_name":"Maintenance treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tudorza Pressair","generic_name":"ACLIDINIUM BROMIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"M3 receptors, beta 2 -adrenergic receptors","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":"DUAKLIR PRESSAIR combines aclidinium, an anticholinergic, and formoterol, a beta 2 -adrenergic agonist, to provide bronchodilation in COPD."},{"drug_id":"rucaparib","indication_name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."},{"drug_id":"salmeterol-xinafoate","indication_name":"Maintenance Treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL XINAFOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"pemetrexed-disodium","indication_name":"Maintenance Treatment of Non-Squamous NSCLC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"budesonide-and-formoterol","indication_name":"Maintenance Treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"budesonide and formoterol","company_name":"National Jewish Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta 2 -adrenoceptor","drug_class":"Corticosteroid [EPC]","quality_score":60,"revenue":null,"mechanism":"Budesonide reduces inflammation, while formoterol relaxes airway muscles, together improving symptoms of COPD and asthma."},{"drug_id":"tiotropium","indication_name":"Maintenance treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TIOTROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"M3 receptors, beta2-adrenoceptors","drug_class":"","quality_score":48,"revenue":null,"mechanism":"STIOLTO RESPIMAT combines tiotropium, an anticholinergic, and olodaterol, a beta-agonist, to achieve bronchodilation through different mechanisms."},{"drug_id":"beclomethasone","indication_name":"maintenance treatment of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qvar Redihaler","generic_name":"BECLOMETHASONE","company_name":"Norton Waterford","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"flovent-500mcg","indication_name":"Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLOVENT 500mcg","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor (GR)","drug_class":"Inhaled corticosteroid (ICS)","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07137884","title":"Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06441344","title":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":136,"lead_sponsor_name":"Taizhou Hospital","has_results":false},{"nct_id":"NCT07300514","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06256627","title":"The Maintenance Treatment of \"ITIVA\" in AML Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03129698","title":"The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Junling Li","has_results":false},{"nct_id":"NCT04445038","title":"Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT07020052","title":"Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}